Atherosclerosis in chronic kidney disease: more, less, or just different?
JM Valdivielso, D Rodríguez-Puyol… - … , and vascular biology, 2019 - Am Heart Assoc
Patients with chronic kidney disease (CKD) are at an increased risk of premature mortality,
mainly from cardiovascular causes. The association between CKD on hemodialysis and …
mainly from cardiovascular causes. The association between CKD on hemodialysis and …
Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease
N Ueda, K Takasawa - Nutrients, 2018 - mdpi.com
Iron deficiency anemia (IDA) is a major problem in chronic kidney disease (CKD), causing
increased mortality. Ferritin stores iron, representing iron status. Hepcidin binds to …
increased mortality. Ferritin stores iron, representing iron status. Hepcidin binds to …
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis
R Provenzano, E Shutov, L Eremeeva… - Nephrology Dialysis …, 2021 - academic.oup.com
Background We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the
treatment of chronic kidney disease-related anemia in patients new to dialysis. Methods …
treatment of chronic kidney disease-related anemia in patients new to dialysis. Methods …
The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes—a systematic literature review
E Palaka, S Grandy, H van Haalen… - International journal …, 2020 - Wiley Online Library
Anaemia is a common consequence of chronic kidney disease (CKD); however, the risk
factors for its development and its impact on outcomes have not been well synthesised …
factors for its development and its impact on outcomes have not been well synthesised …
Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: a randomized clinical trial
AK Singh, B Cizman, K Carroll… - JAMA internal …, 2022 - jamanetwork.com
Importance Daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is being
evaluated as an oral alternative to conventional erythropoiesis-stimulating agent (ESA) …
evaluated as an oral alternative to conventional erythropoiesis-stimulating agent (ESA) …
Investigating the relationship between erythropoiesis-stimulating agents and mortality in hemodialysis patients: A systematic review and meta-analysis
Z Karimi, H Raeisi Shahraki… - Plos one, 2023 - journals.plos.org
Background In recent years, various studies have been conducted to investigate the
relationship between erythropoiesis-stimulating agents (ESAs) and mortality in hemodialysis …
relationship between erythropoiesis-stimulating agents (ESAs) and mortality in hemodialysis …
Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis
R Pérez-García, J Varas, A Cives… - Nephrology Dialysis …, 2018 - academic.oup.com
Abstract Background Erythropoiesis-stimulating agents (ESAs) are widely used to treat
anaemia in patients with chronic kidney disease. The issue of ESA safety has been raised in …
anaemia in patients with chronic kidney disease. The issue of ESA safety has been raised in …
Relationships among the dosage of erythropoiesis-stimulating agents, erythropoietin resistance index, and mortality in maintenance hemodialysis patients
S Pan, DL Zhao, P Li, XF Sun, JH Zhou, KK Song… - Blood …, 2022 - karger.com
Background: Erythropoiesis-stimulating agents (ESAs) constitute an important treatment
option for anemia in hemodialysis (HD) patients. We investigated the relationships among …
option for anemia in hemodialysis (HD) patients. We investigated the relationships among …
[HTML][HTML] Erythropoiesis-stimulating agents and cardiovascular mortality: A systematic review and meta-analysis of 17 studies and 372,156 hemodialysis patients
Z Karimi, HR Shahraki… - International Journal of …, 2023 - Elsevier
Introduction Prior studies on the association between erythropoiesis-stimulating agents
(ESAs) and cardiovascular mortality in hemodialysis patients have yielded conflicting …
(ESAs) and cardiovascular mortality in hemodialysis patients have yielded conflicting …
Risk factors associated with cardiovascular morbidity and mortality in Spanish incident hemodialysis patients: two-year results from the ANSWER study
Aims: To identify factors associated with cardiovascular (CV) disease in hemodialysis.
Methods: Multicenter, prospective, 2-year, observational study in 2,310 incident patients …
Methods: Multicenter, prospective, 2-year, observational study in 2,310 incident patients …